Novartis India launches Pluvicto for prostate cancer treatment

▤ Summary

Novartis India has launched Pluvicto, a radioligand therapy for eligible patients with PSMA-positive prostate cancer. The company says the treatment targets cancer cells more precisely while limiting exposure to healthy tissue. It positions the launch as an expansion of advanced oncology care in India, where prostate cancer rates and metastatic diagnoses are rising. Novartis also says it will work with hospitals, oncologists, and nuclear medicine specialists to support access and treatment readiness across select centres.

▦ Linked Companies